Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Stock Information for Candel Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Candel Therapeutics Inc.

Rezolute to Participate in Upcoming Investor Conferences
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
Rezolute to Participate in Upcoming Investor Conferences
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.